Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Enters The Alzheimer’s Disease Race, Plans Filings For Five New Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

As Merck heads into a “patent cliff” year, highlights of its analyst meeting included updates on key Phase III drugs, growth in emerging markets, and unveiling of new programs in Alzheimer’s disease and diabetes.

Advertisement

Related Content

Lilly Ends Trial Of BACE Inhibitor For Alzheimer’s, But Says Class-Wide Safety Effect Unlikely
Merck On Track To File Novel Sleep Aid Suvorexant In 2012
Diabetes Franchise May Help Merck Offset Loss Of Singulair
Merck On Track To File Novel Sleep Aid Suvorexant In 2012
Merck Looks Beyond First-In-Class Only As It Seeks To Bolster R&D Productivity
Merck Looks Beyond First-In-Class Only As It Seeks To Bolster R&D Productivity
Merck Makes Hepatitis C A Priority
Merck Adds To Diabetes Franchise With SmartCells Acquisition
Merck R&D: A Jam-Packed Pipeline, But Much Of It Is Wait-And-See

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS073040

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel